These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 12795099

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R, Tanabe K, Emi M, Uchida Y, Osaki A, Toge T.
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [Abstract] [Full Text] [Related]

  • 5. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
    Masuoka H, Mori M, Nomura N, Sakurai M, Yoshida K, Usuda N, Shirai H, Shimokawara I, Asaishi K.
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
    [Abstract] [Full Text] [Related]

  • 6. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, Bolton JL.
    Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
    [Abstract] [Full Text] [Related]

  • 7. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
    Han GZ, Liu ZJ, Shimoi K, Zhu BT.
    Cancer Res; 2005 Jan 15; 65(2):387-93. PubMed ID: 15695378
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
    Tabuchi Y, Matsuoka J, Gunduz M, Imada T, Ono R, Ito M, Motoki T, Yamatsuji T, Shirakawa Y, Takaoka M, Haisa M, Tanaka N, Kurebayashi J, Jordan VC, Naomoto Y.
    Int J Oncol; 2009 Feb 15; 34(2):313-9. PubMed ID: 19148464
    [Abstract] [Full Text] [Related]

  • 13. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
    Yamamoto Y, Kawazoe T, Iwase H.
    Gan To Kagaku Ryoho; 2005 Oct 15; 32(10):1415-9. PubMed ID: 16227740
    [Abstract] [Full Text] [Related]

  • 14. The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance.
    Lehenkari P, Parikka V, Rautiala TJ, Weckström M, Dahllund J, Härkönen PL, Väänänen HK.
    J Bone Miner Res; 2003 Mar 15; 18(3):473-81. PubMed ID: 12619932
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells.
    Baker WJ, Maenpaa JU, Wurz GT, Koester SK, Seymour RC, Emshoff VD, Wiebe VJ, DeGregorio MW.
    Oncol Res; 1993 Mar 15; 5(6-7):207-12. PubMed ID: 8123940
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
    Sakurai K, Enomoto K, Amano S.
    Gan To Kagaku Ryoho; 2010 Nov 15; 37(12):2246-8. PubMed ID: 21224536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.